DEI/Health Equity
1
Date of Presentation
5-2-2024 12:00 AM
College
Rowan-Virtua School of Osteopathic Medicine
Poster Abstract
In low to middle income countries, there's a rise in invasive cervical squamous cell carcinoma. Affordability emerges as a crucial factor influencing this trend. This research is based on the development of a new HPV vaccine made in China called Ceolin priced at $47 and its efficacy to be incorporated into the WHO vaccination program. A peer review was conducted based on an ongoing randomized phase 3 clinical trial of a 2 dose regimen bivalent Cecolin vaccine (types 16,18) . The study includes 1025 females aged 9-14 years old split amongst 5 groups. The control group received Gardasil at the following intervals: 0 and 6 months. Experimental groups received Cecolin at the following intervals: 6-, 12-, 24-month or one dose of Gardasil followed by one dose of Cecolin at month 24. Outcome measures assessed Anti-HPV16 and 18 antibodies. Data for the 6 month dosing group showed that 96% of participants had antibody positive development for both HPV strains following Cecolin administration and produced a comparable immune response to Gardasil. IgG levels for HPV 16 of Cecolin and Gardasil were 1,567 and 1,444 IU/mL, respectively, and 424 and 336 IU/mL, respectively, for HPV-18. The potential incorporation of Cecolin into the WHO vaccination program can expand vaccine options, leading to improvements in accessibility when offering cost effective options to consumers as well as decreasing the incidence of cervical cancer in underdeveloped countries. HPV vaccinations align with osteopathic medicine principles of preventative care, preventing health disparities and patient education.
Keywords
WHO vaccination program, Immunization Programs, World Health Organization, Vaccines, Human Papilloma Virus, HPV vaccines, Cecolin, Gardasil, cervical cancer, Cancer Vaccines, Low Income Countries, Child, Female
Disciplines
Female Urogenital Diseases and Pregnancy Complications | Health and Medical Administration | Infectious Disease | International Public Health | Medicine and Health Sciences | Neoplasms | Pharmaceutical Preparations | Public Health Education and Promotion | Virus Diseases | Women's Health
Document Type
Poster
DOI
10.31986/issn.2689-0690_rdw.stratford_research_day.112_2024
YouTube Video Link
Included in
Female Urogenital Diseases and Pregnancy Complications Commons, Health and Medical Administration Commons, Infectious Disease Commons, International Public Health Commons, Neoplasms Commons, Pharmaceutical Preparations Commons, Public Health Education and Promotion Commons, Virus Diseases Commons, Women's Health Commons
What is the Efficacy of the Newly Developed HPV Vaccine, Cecolin, in Providing Protection Against HPV-Induced Cervical Cancers in Females Aged 9-14 Years Old
In low to middle income countries, there's a rise in invasive cervical squamous cell carcinoma. Affordability emerges as a crucial factor influencing this trend. This research is based on the development of a new HPV vaccine made in China called Ceolin priced at $47 and its efficacy to be incorporated into the WHO vaccination program. A peer review was conducted based on an ongoing randomized phase 3 clinical trial of a 2 dose regimen bivalent Cecolin vaccine (types 16,18) . The study includes 1025 females aged 9-14 years old split amongst 5 groups. The control group received Gardasil at the following intervals: 0 and 6 months. Experimental groups received Cecolin at the following intervals: 6-, 12-, 24-month or one dose of Gardasil followed by one dose of Cecolin at month 24. Outcome measures assessed Anti-HPV16 and 18 antibodies. Data for the 6 month dosing group showed that 96% of participants had antibody positive development for both HPV strains following Cecolin administration and produced a comparable immune response to Gardasil. IgG levels for HPV 16 of Cecolin and Gardasil were 1,567 and 1,444 IU/mL, respectively, and 424 and 336 IU/mL, respectively, for HPV-18. The potential incorporation of Cecolin into the WHO vaccination program can expand vaccine options, leading to improvements in accessibility when offering cost effective options to consumers as well as decreasing the incidence of cervical cancer in underdeveloped countries. HPV vaccinations align with osteopathic medicine principles of preventative care, preventing health disparities and patient education.